Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07275996

Neuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty

Sarcopenia and physical frailty are highly prevalent among institutionalized older adults and are major contributors to functional decline, reduced mobility, and loss of independence. Combined exercise and targeted nutritional strategies have emerged as promising approaches to mitigate these age-related impairments.

This randomized, double-blind, placebo-controlled, parallel-group clinical trial aims to evaluate the independent and combined effects of creatine monohydrate (CRE) and β-hydroxy-β-methylbutyrate (HMB), administered alongside a supervised multicomponent exercise program, on physical function, body composition, cognitive performance, and quality of life in institutionalized older adults with physical frailty and sarcopenia.

A total of 50 adults aged ≥65 years were enrolled and randomized to one of four intervention groups for 12 weeks: placebo plus exercise, creatine plus exercise, HMB plus exercise, or creatine plus HMB plus exercise. A supplement-free follow-up period will be conducted to evaluate the sustainability of intervention effects.

In addition to clinical and functional outcomes, the study incorporates molecular and biological assessments to explore mechanistic pathways underlying functional adaptation and interindividual variability in response to the interventions.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Residencia de Mayores Fuentes Blancas (Diputación Provincial de Burgos)

Burgos, Castille and León, 09002, Spain

About this study

This randomized, double-blind, placebo-controlled, parallel-group clinical trial is designed to evaluate the independent and combined effects of creatine monohydrate (CRE) and β-hydroxy-β-methylbutyrate (HMB) supplementation when administered alongside a structured multicomponent exercise program in institutionalized older adults with physical frailty and sarcopenia. Sarcopenia and frailty are highly prevalent in this population and are associated with functional disability, increased health care utilization, and reduced quality of life. Nutritional strategies targeting muscle metabolism, when combined with systematic exercise, may attenuate functional decline and improve health outcomes in this vulnerable group.

Study Population and Design

A total of 50 institutionalized adults aged ≥65 years were enrolled from nursing homes in the province of Burgos (Spain). Participants were stratified by sex and randomized to one of four parallel intervention groups for a 12-week intervention period: placebo plus exercise, creatine plus exercise, HMB plus exercise, or creatine plus HMB plus exercise. All intervention groups will be followed by a supplement-free follow-up period to assess the persistence of intervention effects.

Intervention

Dietary supplementation will be administered once daily using identical sachets to ensure blinding and equivalent supplement volume across groups. Participants will receive a total of 6 g/day of powder, consisting of cellulose (placebo), creatine monohydrate, HMB, or their combinations, depending on group allocation. Supplement administration will be supervised by nursing staff and mixed with food or beverages according to standard procedures.

All participants will complete a supervised multicomponent exercise program conducted four times per week (~60 minutes per session). Exercise sessions will include resistance, balance, coordination, and flexibility training, with intensity individually adapted according to functional capacity using the Borg Rating of Perceived Exertion Scale.

Outcomes and Assessments

Clinical, functional, cognitive, and quality-of-life assessments will be conducted at baseline, post-intervention (Week 12), and during follow-up. Primary and secondary outcome measures focus on physical performance, muscle strength, body composition, cognitive function, activities of daily living, nutritional status, and quality of life.

Molecular and Biological Assessments

In addition to clinical outcomes, the study incorporates biological and molecular assessments to explore mechanistic pathways underlying functional adaptation and interindividual variability in response to supplementation and exercise. Venous blood samples will be collected for the analysis of inflammatory markers, oxidative stress and antioxidant status, hormonal profiles, and circulating and exosomal molecular signatures related to muscle metabolism and neuromuscular function. Body composition parameters will be assessed using dual-energy X-ray absorptiometry (DXA).

Statistical Analysis

Statistical analyses will be conducted using mixed-effects models appropriate for parallel-group randomized designs, with treatment group, time, and their interaction as fixed effects, and sex and age included as covariates where appropriate. Post-hoc pairwise comparisons will be adjusted for multiple testing. Statistical significance will be set at p < 0.05.

Ethics and Data Protection

The study was approved by the Ethics Committee of the University of Burgos (IR 24/2023). Written informed consent was obtained from all participants or their legal representatives. All data will be pseudonymized and managed in accordance with the General Data Protection Regulation (GDPR) and Spanish data protection laws.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Institutionalized older adults (≥65 years) residing in the Fuentes Blancas Nursing Home (Diputación de Burgos).
  • Clinical diagnosis of frailty or sarcopenia according to validated criteria (e.g., Fried phenotype, SPPB ≤ 9, or low ALMI by DEXA).
  • Ability to participate in an exercise program as assessed by the medical staff.
  • Written informed consent provided by the participant or, if cognitively impaired, by a legally authorized representative.

Exclusion criteria

  • Severe renal insufficiency (eGFR < 30 mL/min/1.73m²) or liver failure.
  • Advanced heart failure (NYHA class III-IV) or unstable cardiovascular disease.
  • Active cancer or other severe medical conditions that contraindicate participation.
  • Severe cognitive impairment (MMSE < 10) precluding adherence to the program without caregiver support.
  • Known allergy or intolerance to creatine, HMB, or inulin.
  • Participation in another clinical trial within the past 3 months.
  • Any condition that, in the opinion of the medical team, may compromise safety or adherence to the intervention.

Treatment and study plan

Placebo (Cellulose)

Dietary Supplement

Sachets containing cellulose used as placebo filler to match supplement volume, appearance, and taste. Administered once daily, mixed with yogurt or juice, during the intervention period.

Creatine Monohydrate

Dietary Supplement

Sachets containing creatine monohydrate used as an active dietary supplement. Administered once daily during the intervention period.

Multicomponent Exercise Program

Behavioral

Supervised exercise sessions, 4 times per week (~60 minutes each), including resistance, endurance, balance, coordination, and flexibility training. Intensity adapted to participants' functional status (Borg scale 6-9). Conducted throughout the 12-week intervention period.

β-Hydroxy-β-Methylbutyrate (HMB)

Dietary Supplement

Sachets containing calcium β-hydroxy-β-methylbutyrate used as an active dietary supplement. Administered once daily during the intervention period.

Primary outcomes

  1. Short Physical Performance Battery (SPPB)

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    The SPPB assesses lower-extremity physical function through balance, gait speed, and chair stand components, generating a total score ranging from 0 to 12 (higher scores indicate better physical performance). Only the total score will be analyzed as the primary outcome.

  2. Timed Up and Go (TUG)

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Time in seconds to rise from a chair, walk 3 meters, turn around, return, and sit down. Lower times indicate better mobility and balance.

  3. Appendicular Lean Mass (ALM, kg) by DEXA

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Appendicular lean mass (sum of arms and legs lean tissue) measured in kilograms using DEXA. Higher values indicate greater muscle mass in limbs.

Secondary outcomes

  1. Grip Strength

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Maximal isometric handgrip strength measured in kilograms using a validated hydraulic dynamometer (e.g., Jamar Plus+). Each test performed with the dominant hand in seated position, elbow at 90°. Best of three attempts recorded.

  2. Leg and Back Isometric Strength

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Maximal isometric strength of leg and back extensors assessed in kilograms using a back/leg dynamometer (e.g., Baseline Evaluation Dynamometer). Participants stand on the platform and pull a fixed bar upwards. Best of two attempts recorded.

  3. Seated Arm Curl Test

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Dynamic strength/endurance of upper limbs measured as the number of full arm curl repetitions in 30 seconds using a 2 kg dumbbell for women and a 4 kg dumbbell for men. Participants are seated upright without armrests.

  4. Barthel Index

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Measure of independence in activities of daily living (feeding, bathing, mobility, toileting, etc.). Score ranges from 0 (total dependence) to 100 (independent).

  5. Mini Nutritional Assessment (MNA)

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Validated tool to screen and assess nutritional status in older adults. Score ranges from 0-30 (higher = better nutritional status).

  6. Cognitive Function - Mini-Mental State Examination (MMSE)

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Cognitive function assessed using the Mini-Mental State Examination (MMSE). Scores range from 0 to 30, with higher scores indicating better cognition.

  7. Quality of Life - World Health Organization Quality of Life-Brief (WHOQOL-BREF)

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    26-item validated questionnaire covering physical, psychological, social and environmental domains.

    Scores range from 26 to 130; higher scores indicate better perceived quality of life.

  8. Total Lean Mass (kg) by DEXA

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Whole-body lean soft tissue mass measured in kilograms using DEXA (Hologic Discovery or GE Lunar system) with manufacturer's software and standardized positioning. Higher values indicate greater muscle mass.

  9. Total Fat Mass (percent body weight) by DEXA

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Whole-body fat mass measured with DEXA and expressed as a percentage of total body weight. Higher values indicate greater adiposity.

  10. Visceral Adipose Tissue (VAT, cm³) by DEXA

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Visceral adipose tissue (VAT) volume estimated by DEXA in the android region of interest, expressed in cubic centimeters (cm³). Higher values indicate greater central adiposity.

  11. Whole-Body Bone Mineral Density (BMD, g/cm²) by DEXA

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Whole-body BMD measured by DEXA, expressed as grams per square centimeter (g/cm²). Higher values indicate greater bone mineral density.

  12. Cognitive Function - MEC (Spanish Adaptation of MMSE)

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Cognitive function assessed using the MEC (Spanish version of the MMSE). Scores range from 0 to 35, with higher scores indicating better cognition.

  13. Number of Falls

    Time frame: Baseline to 3-month follow-up

    Incidence of falls recorded by nursing staff during the study period. Unit: number of events per participant. Lower numbers indicate better outcomes.

  14. Number of Hospitalizations

    Time frame: Baseline to 3-month follow-up

    Incidence of hospital admissions for any cause. Unit: number of events per participant. Lower numbers indicate better outcomes.

  15. Incidence of Respiratory and Urinary Infections

    Time frame: Baseline to 3-month follow-up

    Number of documented respiratory and/or urinary tract infections. Unit: number of events per participant. Lower numbers indicate better outcomes.

  16. Incidence of Pressure Ulcers

    Time frame: Baseline to 3-month follow-up

    Number of new pressure ulcers recorded by nursing staff. Lower numbers indicate better outcomes.

  17. Incidence of Urinary or Fecal Incontinence

    Time frame: Baseline to 3-month follow-up

    Occurrence of urinary and/or fecal incontinence episodes recorded in clinical charts. Lower numbers indicate better outcomes.

  18. Serum C-reactive protein (CRP, mg/L)

    Time frame: Baseline, Week 12 (end of intervention)

    CRP will be measured in serum samples using a high-sensitivity ELISA. Results expressed in mg/L. Higher values indicate greater systemic inflammation.

  19. Interleukin-6 (IL-6, pg/mL)

    Time frame: Baseline, Week 12 (end of intervention)

    Serum IL-6 concentration will be measured by ELISA and expressed in pg/mL. Higher values indicate greater systemic inflammation.

  20. Tumor Necrosis Factor-alpha (TNF-α, pg/mL)

    Time frame: Baseline, Week 12 (end of intervention)

    Serum TNF-α concentration will be determined by ELISA and expressed in pg/mL. Higher values indicate greater systemic inflammation.

  21. Reduced Glutathione (GSH, µmol/L)

    Time frame: Baseline, Week 12 (end of intervention)

    Plasma reduced glutathione measured by colorimetric assay and expressed in µmol/L. Higher values indicate better antioxidant status.

  22. Oxidized Glutathione (GSSG, µmol/L)

    Time frame: Baseline, Week 12 (end of intervention)

    Plasma oxidized glutathione measured by colorimetric assay and expressed in µmol/L. Higher values indicate greater oxidative stress.

  23. Thiobarbituric Acid Reactive Substances (TBARS, nmol MDA equivalents/mL plasma)

    Time frame: Baseline, Week 12 (end of intervention)

    Lipid peroxidation index measured as TBARS and expressed in nmol MDA equivalents/mL of plasma. Higher values indicate greater oxidative stress.

  24. Malondialdehyde (MDA, µmol/L)

    Time frame: Baseline, Week 12 (end of intervention)

    Plasma MDA determined spectrophotometrically and expressed in µmol/L. Higher values indicate greater oxidative stress.

  25. Total Antioxidant Capacity (TAC, mmol Trolox equivalents/L)

    Time frame: Baseline, Week 12 (end of intervention)

    Plasma TAC measured using colorimetric assay and expressed as mmol Trolox equivalents/L. Higher values indicate better antioxidant defense.

  26. Relative expression levels of selected circulating microRNAs

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

    Changes in the relative expression levels of selected circulating microRNAs associated with muscle metabolism, neuromuscular function, inflammation, oxidative stress, and anabolic signaling pathways. MicroRNAs will be quantified from peripheral blood samples using molecular profiling techniques.

  27. Relative expression levels of selected exosome-derived microRNAs

    Time frame: Baseline and Week 12

    Changes in the relative expression levels of selected exosome-derived microRNAs related to muscle function, inflammation, and metabolic regulation, analyzed from circulating extracellular vesicles isolated from plasma samples.

  28. Frequency of selected genetic variants related to creatine and HMB responsiveness

    Time frame: Baseline

    Analysis of the frequency of selected genetic variants related to muscle metabolism, anabolic signaling, and exercise responsiveness to explore interindividual variability in functional and molecular responses to creatine and HMB supplementation.

  29. Relative abundance of selected circulating proteins involved in muscle and inflammatory responses

    Time frame: Baseline and Week 12

    Changes in the relative abundance of selected circulating proteins involved in muscle metabolism, inflammation, oxidative stress, and functional adaptation in response to creatine and HMB supplementation combined with exercise. Protein abundance will be assessed using targeted proteomic approaches.

Sponsors and collaborators

Lead sponsor

Universidad de Burgos

Other

Registry information

Official study title

Effects of Creatine Monohydrate and β-Hydroxy-β-Methylbutyrate Supplementation Combined With Multicomponent Exercise on Physical Performance, Cognition and Quality of Life in Institutionalized Older Adults: A Randomized Double-Blind Parallel-Group Trial

Acronym: MULTI-FRAIL

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Dec 10, 2025
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.